Gilead was able to bully Remdesivir to the top of the approval foodchain using its lobbying power but now the WHO findings refute the effectiveness of the drug. The only viable clinical trial left in the pipeline showing a mortality benefit is called leronlimab. CytoDyn the drug developer, was outmatched in its ability to attract patients into its trials due to the hastily issued Emergency Use Approval of remdesivir. The FDA approval of remdesivir might actually help leronlimab make a comeback because the efficacy of remdesivir is so poor that doctors can now look to one of the most promising therapies on the horizon and help them complete enrollment in their clinical trial.
The video splices together Elon Musk's statements regarding Full Self Driving, which he has been collecting deposits on for years, with clips of the "feature's" recent performance.
